Optimizing treatment for idiopathic inflammatory myopathies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to optimize treatment for patients with idiopathic inflammatory myopathies by comparing two groups receiving different pulse therapies. Patients will either receive a combination of methylprednisolone and human intravenous immunoglobulin or just methylprednisolone at the onset of their disease. The study follows an internal routine protocol of the service at the University of Sao Paulo, focusing on the effectiveness of these treatment regimens.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Idiopathic inflammatory myopathies

Exclusion Criteria:

* Inclusion body myositis, muscular dystrophies, neoplasia-associated myopathies, overlapped myopathies, others myopathies

Where it's running

• Samuel Katsuyuki Shinjo
  São Paulo, Brazil Recruiting

Study contacts

• Principal investigator: Samuel K Shinjo, PhD — Universidade de Sao Paulo - Rheumatology Division
• Study coordinator: Samuel K Shinjo, PhD
• Email: samuel.shinjo@gmail.com
• Phone: 55-11-3061-7176

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MTS109 treatment for refractory autoimmune diseases

  This trial tests whether MTS109 (an mRNA-LNP given by subcutaneous injection) is safe and tolerable in adults with moderate to severe autoimmune diseases that have not responded to standard treatments.

  Recruiting Early Phase 1 Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT07526350

• AZD0120 CD19/BCMA CAR T-cell therapy for systemic sclerosis, inflammatory myopathies, and difficult-to-treat rheumatoid arthritis

  This trial will try a dual-targeting CD19/BCMA CAR T-cell treatment (AZD0120) in adults with systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis to see if it is safe and well tolerated.

  Recruiting at 5 sites Phase 1/2 AstraZeneca · Tucson, Arizona and 26 other locations · NCT07295847

• Phase 1 safety test of XmAb657 in healthy adults and people with myositis, scleroderma, or Sjögren's

  This study will test whether subcutaneous injections of XmAb657 are safe and well tolerated in healthy adults and people with autoimmune diseases such as idiopathic inflammatory myopathies, systemic sclerosis, or primary Sjögren's syndrome.

  Recruiting Phase 1 Xencor, Inc. · Melbourne · NCT07284797

• Imaging in Inflammatory Heart Diseases linked to autoimmune disorders

  This study tests how well multimodality imaging (CMR, echocardiography, and PET) detects inflammation in people with suspected inflammatory heart or autoimmune rheumatic diseases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07077304

• BAFF‑R CAR T‑cell treatment for refractory neuroimmune diseases

  This trial will try personalized BAFF‑R CAR T cells to reduce disease activity in people with hard‑to‑treat conditions such as CIDP, NMOSD, myasthenia gravis, and inflammatory myopathies.

  Recruiting Phase 1/2 Tianjin Medical University General Hospital · Tianjin, Tianjin Municipality · NCT07022197

• Investigating AZD5492 for treating systemic lupus erythematosus and inflammatory myopathies

  This study is testing a new medication called AZD5492 to see if it can safely help adults with systemic lupus erythematosus and inflammatory myopathies feel better.

  Recruiting at 33 sites Phase 1 AstraZeneca · Anniston, Alabama and 37 other locations · NCT06916806

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.